HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on WAVE Life Sciences and increased the price target from $15 to $22, indicating a positive outlook for the company's stock.
September 25, 2024 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on WAVE Life Sciences and increased the price target from $15 to $22, suggesting a positive short-term outlook for the stock.
The increase in price target from $15 to $22 by HC Wainwright & Co. indicates a strong positive sentiment from the analyst, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100